RxDoctor Payments Data

Kenneth Grier, MD

Family Medicine · Apple Valley, CANPI 1114235744

Payments from drug & device makers

$1,933in general payments, 2019–2025

Across 102 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$446
  • AstraZeneca$375
  • Boehringer Ingelheim$227
  • GSK$129
  • Pfizer$102
  • Bayer$77
  • plus $579 from 20 others

What the payments were for

  • Food & beverage$1,933100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,933 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$57,222
Medicare patients
137
Services billed
529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin81$90,840
EliquisApixaban137$71,751
TrulicityDulaglutide38$45,399
JanuviaSitagliptin Phosphate42$31,385
OzempicSemaglutide32$30,029
FarxigaDapagliflozin Propanediol34$28,569
RybelsusSemaglutide11$21,895
Spiriva RespimatTiotropium Bromide25$16,243
XareltoRivaroxaban23$12,887
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,213
LinzessLinaclotide13$8,649
GemtesaVibegron13$7,644
GlyxambiEmpagliflozin/Linagliptin12$6,968
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$5,160
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Glyxambi$227$114,051118 claims
PfizerEliquis$102$71,751137 claims
Novo NordiskOzempic, Rybelsus$32$51,92343 claims
Lilly USA, LLCTrulicity$446$45,39938 claims
MerckJanuvia$15$31,38542 claims
AstraZenecaFarxiga$375$28,56934 claims
Johnson & JohnsonXarelto$51$12,88723 claims
GSKTrelegy Ellipta$129$12,21317 claims
Astellas Pharma US IncMyrbetriq$24$3,96411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →